PFO
XFOR icon

Pathstone Family Office’s X4 Pharmaceuticals XFOR Stock Holding History

Pathstone Family Office’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$13.8K Buy
+421
New +$18.4K ﹤0.01% 1652

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TLP
Tri Locum Partners New York $813M AUM 101.01% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pathstone Family Office's XFOR Position: Q3 2023 in Review

Pathstone Family Office opened a new position in X4 Pharmaceuticals (XFOR) in Q3 2023: 421 shares worth $13.8K. The stake represents ﹤0.01% of the portfolio and ranks #1652 among its holdings.

91 funds tracked by Wall St. Rank hold XFOR as of Q3 2023.

  • Pathstone Family Office held 421 shares of X4 Pharmaceuticals worth $13.8K as of Q3 2023.
  • X4 Pharmaceuticals was a new Pathstone Family Office position in Q3 2023.
  • X4 Pharmaceuticals made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1652 holding.
  • 91 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.